nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.11.2020 | Original Article – Cancer Research

Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer

verfasst von: Juan Yang, ZhouXue Wu, Yao Chen, ChuanFei Hu, Dong Li, Yue Chen, Saber Imani, QingLian Wen, ShaoZhi Fu, JingBo Wu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The hypoxic microenvironments of solid tumours are complex and reduce the susceptibility of cancer cells to chemo- and radiotherapy. Conventional radiosensitisers have poor specificity, unsatisfactory therapeutic effects, and significant side effects. Anaerobic bacteria colonise and destroy hypoxic areas of the tumour and consequently enhance the effects of radiation.

Methods

In this study, we treated a Lewis lung carcinoma transplant mouse model with Bifidobacterium infantis (Bi) combined with its specific monoclonal antibody (mAb) and radiotherapy (RT) to investigate its ability to radiosensitise the tumour. The tumour metabolism and hypoxia in the tumour tissue were monitored by micro-¹⁸F-FDG and ¹⁸F-FMISO PET/CT imaging. Immunohistochemistry was used to detect phosphorylated histone (γ-H2AX), proliferation (Ki-67), platelet endothelial cell adhesion molecules (CD31), tumour necrosis factor-α (TNF-α), hypoxia-inducible factor-1α (HIF-1α), and glucose transporter 1 (Glut-1) levels.

Results

Tumour growth was slowed and survival time was markedly prolonged in mice subjected to the combination of B. infantis, specific antibody, and radiotherapy. Levels of HIF-1α, Glut-1, Ki-67, and CD31 expression, as well as uptake of FDG and FMISO, were the lowest in the combination-treated mice. In contrast, γ-H2AX and TNF-α expression levels were elevated and hypoxia in tumour tissue was reduced compared with controls.

Conclusion

In conclusion, our data indicated that the curative effect of radiotherapy for lung cancer was enhanced by pre-treating mice with a combination of B. infantis and its specific monoclonal antibody.

Bettegowda C, Dang LH et al (2003) Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 100(25):15083–15088. https://doi.org/10.1073/pnas.2036598100CrossRefPubMedPubMedCentral

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(394–68):424. https://doi.org/10.3322/caac.21492CrossRef

Bristow RG, Hill RP (2008) Hypoxia and metabolism hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192. https://doi.org/10.1038/nrc2344CrossRefPubMed

Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4(6):437–447. https://doi.org/10.1038/nrc1367CrossRefPubMed

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249–257. https://doi.org/10.1038/35025220CrossRefPubMed

Chmura SJ, Gupta N, Advani SJ, Kufe DW, Weichselbaum RR (2001) Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol 11(338–11):345. https://doi.org/10.1053/srao.2001.26019CrossRef

Crino L, Weder W, van Meerbeeck J, Felip E, Group EGW (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v103–v115. https://doi.org/10.1093/annonc/mdq207CrossRef

Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98(26):15155–15160. https://doi.org/10.1073/pnas.251543698CrossRefPubMedPubMedCentral

Dueñas-Gonzalez A, Cetina L, Mariscal I, Garza J (2003) Modern management of locally advanced cervical carcinoma. Cancer Treat Rev 29(5):389–399. https://doi.org/10.1016/s0305-7372(03)00068-9CrossRefPubMed

Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159. https://doi.org/10.1126/science.1082504CrossRefPubMed

Glatzel-Plucinska N, Piotrowska A, Grzegrzolka J, Olbromski M, Rzechonek A, Dziegiel P, Podhorska-Okolow M (2018) SATB1 level correlates with Ki-67 expression and is a positive prognostic factor in non-small cell lung carcinoma. Anticancer Res 38(2):723–736. https://doi.org/10.21873/anticanres.12278CrossRefPubMed

Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D (2004) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7(6):492–508. https://doi.org/10.1016/j.ijrobp.2008.04.052CrossRef

Havell EA, Fiers W, North RJ (1988) The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167(3):1067–1085. https://doi.org/10.1084/jem.167.3.1067CrossRefPubMed

Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3(2):177–182. https://doi.org/10.1038/nm0297-177CrossRefPubMed

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515PubMed

Hung MS, Wu YF, Chen YC (2019) Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: a meta-analysis and systematic review. Medicine (Baltimore) 98:e16167. https://doi.org/10.1097/MD.0000000000016167CrossRef

Jiang Y, Allen D, Kersemans V, Devery AM, Bokobza SM, Smart S, Ryan AJ (2015) Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung Cancer 90(2):191–198. https://doi.org/10.1016/j.lungcan.2015.08.009CrossRefPubMed

Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW et al (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22(1):199–212. https://doi.org/10.1016/0360-3016(92)91001-4CrossRefPubMed

Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, Sato K, Fukuda H et al (1999) Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 26(7):750–757. https://doi.org/10.1007/s002590050446CrossRefPubMed

Luo CH, Huang CT, Su CH, Yeh CS (2016) Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett 16(6):3493–3499. https://doi.org/10.1021/acs.nanolett.6b00262CrossRefPubMed

Van MAbbeele AD (2008) The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8–13. https://doi.org/10.1634/theoncologist.13-S2-8CrossRef

Machtay M, Paulus R, Moughan J, Komaki R, Bradley JE, Choy H, Albain K, Movsas B, Sause WT, Curran WJ (2012) Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol 7(716–7):722. https://doi.org/10.1097/JTO.0b013e3182429682CrossRef

Mah LJ, El-Osta A, Karagiannis TC (2010) gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24(4):679–686. https://doi.org/10.1038/leu.2010.6CrossRefPubMed

McGinn CJ, Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 11(270–11):280. https://doi.org/10.1053/srao.2001.26002CrossRef

Melillo G (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26(2):341–352. https://doi.org/10.1007/s10555-007-9059-xCrossRefPubMed

Ni XL, Chen LX, Zhang H, Yang B, Xu S, Wu M, Liu J, Yang LL et al (2017) In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer. Drug Deliv 24(1):1501–1512. https://doi.org/10.1080/10717544.2017.1384862CrossRefPubMedPubMedCentral

Phase I/II study (2014) APS001F with flucytosine and maltose in solid tumors (ClinicalTrials.gov Identifier: NCT01562626, last verified. https://clinicaltrials.gov/ct2/show/NCT01562626).

Provencio M, Sanchez A, Garrido P, Valcarcel F (2010) New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 11(91–11):97. https://doi.org/10.3816/CLC.2010.n.012CrossRef

Ranjan AP, Mukerjee A, Gdowski A, Helson L, Bouchard A, Majeed M, Vishwanatha JK (2016) Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer. J Biomed Nanotechnol 12(4):679–688. https://doi.org/10.1166/jbn.2016.2207CrossRefPubMed

Rasey JS, Casciari JJ, Hofstrand PD, Muzi M, Graham MM, Chin LK (2000) Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole. Radiat Res 153(1):84–92. https://doi.org/10.1667/0033-7587(2000)153[0084:dhfiar]2.0.co;2CrossRefPubMed

Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D et al (2014) Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med 6(249):249CrossRef

Rüegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ (1998) Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4(4):408–414. https://doi.org/10.1038/nm0498-408CrossRefPubMed

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732. https://doi.org/10.1038/nrc1187CrossRefPubMed

Sun CJ, Yang ZG, Zhou XP, Zhou QH, Sun JT, Zhang SF, Li J, Yu JM et al (2007) Non-small cell lung cancer evaluated by first pass dynamic contrast-enhanced 16-slice spiral CT: correlation of tumor vascularity with pathological characteristics. Zhonghua Zhong Liu Za Zhi 29(6):429–433PubMed

Sznol M, Lin SL, Bermudes D, Zheng LM, King I (2000) Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest 105(8):1027–1030. https://doi.org/10.1172/JCI9818CrossRefPubMedPubMedCentral

Teicher BA (1995) Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 9(2):475–506. https://doi.org/10.1016/s0889-8588(18)30105-9CrossRefPubMed

Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33(12):2133–2137PubMed

Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl 3):21–26. https://doi.org/10.1634/theoncologist.13-S3-21CrossRefPubMed

Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 91(957–91):971

Xia Y, Choi HK, Lee K (2012) Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 4(924–4):940. https://doi.org/10.1016/j.ejmech.2012.01.033CrossRef

Xie F, Ding RL, He WF, Liu ZJ, Fu SZ, Wu JB, Yang LL, Lin S et al (2017) In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv 24(1):1410–1418. https://doi.org/10.1080/10717544.2017.1378938CrossRefPubMedPubMedCentral

Xu XD, Shao SX, Jiang HP, Cao YW, Wang YH, Yang XC, Niu HT (2015) Warburg effect or reverse warburg effect? A review of cancer metabolism. Oncol Res Treat 38(3):117–122. https://doi.org/10.1159/000375435CrossRefPubMed

Yang H, Zhong JT, Zhou SH, Han HM (2019) Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer. Oncotarget 10(32):3066–3083. https://doi.org/10.18632/oncotarget.24684CrossRefPubMedPubMedCentral

Yazawa K, Fujimori M, Nakamura T, Sasaki T, Amano J, Kano Y, Taniguchi S (2001) Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat 66(2):165–170. https://doi.org/10.1023/a:1010644217648CrossRefPubMed

Yi C, Huang Y, Guo ZY, Wang SR (2005) Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol Sin 26(5):629–634. https://doi.org/10.1111/j.1745-7254.2005.00094.xCrossRefPubMed

Yu Y, Xu S, You H, Zhang Y, Yang B, Sun X, Yang L, Chen Y et al (2017) In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma. Drug Deliv 24(1):75–82. https://doi.org/10.1080/10717544.2016.1230902CrossRefPubMedPubMedCentral

Titel: Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer
verfasst von: Juan Yang
ZhouXue Wu
Yao Chen
ChuanFei Hu
Dong Li
Yue Chen
Saber Imani
QingLian Wen
ShaoZhi Fu
JingBo Wu
Publikationsdatum: 01.11.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2021
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-020-03434-0

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer